Analyst Ratings For Clementia Pharmaceuticals Inc (NASDAQ:CMTA)
Today, Clementia Pharmaceuticals Inc (NASDAQ:CMTA) stock was downgraded by Robert W. Baird from Outperform to Neutral.
There are 4 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Clementia Pharmaceuticals Inc (NASDAQ:CMTA) is Hold with a consensus target price of $23.60 per share, a potential 8.39% downside.
Some recent analyst ratings include
- 3/4/2019-Clementia Pharmaceuticals Inc (NASDAQ:CMTA) gets downgraded to Neutral by Robert W. Baird
- 2/26/2019-Clementia Pharmaceuticals Inc (NASDAQ:CMTA) gets downgraded to Hold by Bloom Burton
- 2/26/2019-Clementia Pharmaceuticals Inc (NASDAQ:CMTA) gets downgraded to Market Perform by Svb Leerink with a price target of $26.00
- 2/25/2019-Clementia Pharmaceuticals Inc (NASDAQ:CMTA) gets downgraded to Neutral by Wedbush
- 8/31/2017-Clementia Pharmaceuticals Inc (NASDAQ:CMTA) has coverage initiated with a Buy ➝ Buy rating and $32.00 price target
About Clementia Pharmaceuticals Inc (NASDAQ:CMTA)
Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.
Recent Trading Activity for Clementia Pharmaceuticals Inc (NASDAQ:CMTA)
Shares of Clementia Pharmaceuticals Inc closed the previous trading session at 25,76 −0,070 0,27 % with 25.92 shares trading hands.
